Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Martelli

Showing results (531-540 of 549) with videos related to

Pageof 55
Sort By:
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Haematologica|December 20, 1999
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?P L Zinzani, M Martelli, M Magagnoli, et al.
Oncotarget|December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cellsJames A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.
Neurogastroenterology and Motility|April 13, 2018
INPP4B overexpression and c-KIT downregulation in human achalasiaE Bonora, F Bianco, A Stanzani, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Pageof 55

Showing results (531-540 of 549) with videos related to

Sort By:
Pageof 55
Current Pharmaceutical Design|March 8, 2012
Targeting the cancer initiating cell: the ultimate target for cancer therapyJames A McCubrey, Linda S Steelman, Stephen L Abrams, et al.
Haematologica|December 20, 1999
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?P L Zinzani, M Martelli, M Magagnoli, et al.
Oncotarget|December 22, 2016
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cellsJames A McCubrey, Timothy L Fitzgerald, Li V Yang, et al.
Oncogene|March 12, 2008
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitorsL S Steelman, P M Navolanic, M L Sokolosky, et al.
Neurogastroenterology and Motility|April 13, 2018
INPP4B overexpression and c-KIT downregulation in human achalasiaE Bonora, F Bianco, A Stanzani, et al.
Oncotarget|September 26, 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy responseJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Aging|June 15, 2017
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAsJames A McCubrey, Kvin Lertpiriyapong, Linda S Steelman, et al.
Oncotarget|October 23, 2012
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistanceJames A McCubrey, Linda S Steelman, William H Chappell, et al.
Advances in Biological Regulation|November 6, 2019
Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cellsShaw M Akula, Saverio Candido, Stephen L Abrams, et al.
Aging|March 23, 2011
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S Steelman, William H Chappell, Stephen L Abrams, et al.
Pageof 55